Hong Kong: On Sept 4, China’s CanSino Biologics Inc (6185.HK) said that its recently developed COVID-19 vaccine had been approved by the country’s drug regulator for emergency use as a booster. “The approval will have a positive impact on the company’s performance if the vaccine is subsequently purchased and used by relevant government agencies,” CanSino said.
Author
Tags
Share article
The post has been shared by 0
people.